Regulatory T cells and immunoglobulin E: A new therapeutic link for autoimmunity?

Impacto

Downloads

Downloads per month over past year

Palomares, Oscar and Elewaut, Dirk and Irving, Peter M. and Jaumont, Xavier and Tassinari, Paolo (2022) Regulatory T cells and immunoglobulin E: A new therapeutic link for autoimmunity? Allergy . ISSN 0105-4538

[thumbnail of Allergy - 2022 - Palomares - Regulatory T cells and immunoglobulin E  A new therapeutic link for autoimmunity.pdf]
Preview
PDF
Creative Commons Attribution Non-commercial.

4MB

Official URL: https://doi.org/10.1111/all.15449



Abstract

Autoimmune diseases have a prevalence of approximately 7 to 9% and are classified as either organ-specific diseases, including type I diabetes, multiple sclerosis, inflammatory bowel disease and myasthenia gravis, or systemic diseases, including systemic lupus erythematosus, rheumatoid arthritis and Sjögren's syndrome. While many advancements have been made in understanding of the mechanisms of autoimmune disease, including the nature of self-tolerance and its breakdown, there remain unmet needs in terms of effective and highly targeted treatments. T regulatory cells (Tregs) are key mediators of peripheral tolerance and are implicated in many autoimmune diseases, either as a result of reduced numbers or altered function. Tregs may be broadly divided into those generated in the thymus (tTregs) and those generated in the periphery (pTregs). Tregs target many different immune cell subsets and tissues to suppress excessive inflammation and to support tissue repair and homeostasis: there is a fine balance between Treg cell stability and the plasticity that is required to adjust Tregs' regulatory purposes to particular immune responses. The central role of immunoglobulin E (IgE) in allergic disease is well recognized, and it is becoming increasingly apparent that this immunoglobulin also has a wider role encompassing other diseases including autoimmune disease. Anti-IgE treatment restores the capacity of plasmacytoid dendritic cells (pDCs) impaired by IgE- high-affinity IgE receptor (FcεR1) cross-linking to induce Tregs in vitro in atopic patients. The finding that antiIgE therapy restores Treg cell homeostasis, and that this mechanism is associated with clinical improvement in asthma and chronic spontaneous urticaria suggests that antiIgE therapy may also have a potential role in the treatment of autoimmune diseases in which Tregs are involved.


Item Type:Article
Additional Information:

CRUE-CSIC (Acuerdos Transformativos 2022)

Uncontrolled Keywords:anti-IgE, autoimmune disease, immunoglobulin E, omalizumab, regulatory T cells
Subjects:Sciences > Chemistry > Molecular biology
Sciences > Chemistry > Biochemistry
Medical sciences > Medicine > Immunology
ID Code:74174
Deposited On:23 Aug 2022 10:37
Last Modified:23 Aug 2022 10:38

Origin of downloads

Repository Staff Only: item control page